% Expired Patents = 25.0

EPO Patents = 2

Forward Citations = 23

Loading Chart...

2 inventors (with patents filed for the assignee):

Dalia Megiddo (3 out of 16 patents)

Haya Lorberboum-Galski (1 out of 8 patents)

Hagar Greif (1 patent)

4 patents: Sort by Forward Citations

1. 9572825 - Compositions and methods for treating huntington's disease (2017-02-21),

2. 9125924 - Compositions and methods for treating spinocerebellar ataxia (2015-09-08),

3. 9084720 - Compositions and methods for treating oculopharyngeal muscular dystrophy (2015-07-21),

4. 8912147 - Mitochondrial proteins constructs and uses thereof (2014-12-16),

Bioblast Pharma Ltd. is a clinical-stage biotechnology company focused on developing therapies for rare genetic diseases. The company leverages its expertise in mitochondrial biology to create novel treatments for patients with mitochondrial and rare neurodegenerative diseases. Bioblast's pipeline includes innovative drug candidates that target specific aspects of mitochondrial dysfunction, offering hope for patients in need of new treatment options.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

4 Patents

#261 in Tel Aviv

#1,409 in Israel

Tel Aviv, Israel

Bioblast Pharma Ltd.

Forward Citations = 23

2 inventors:

Dalia Megiddo (3 out of 16 patents)

Haya Lorberboum-Galski (1 out of 8 patents)

Hagar Greif (1 patent)

Please report any incorrect information to [email protected]

2 patents (EPO):

Please report any incorrect information to [email protected]